文献速递神经肿瘤

低级别胶质瘤免疫治疗预测面板

Predictive Panel for Immunotherapy in Low-Grade Glioma.
PubMed 文献 · World Neurosurg · 2024-01-11

该研究整合RNA测序数据集与临床信息,通过一致性聚类分析探索适合免疫检查点治疗的低级别胶质瘤患者,识别出3种免疫亚型,其中IS2亚型富含同源重组修复基因突变且免疫检查点基因表达上调最多,并确定NAMPT、SLC11A1、TNC、VIM和SPP1五个标志物可预测免疫检查点阻断疗效且与不良预后相关。

要点

  • 识别出3种低级别胶质瘤免疫亚型,IS2亚型同源重组修复基因突变多、免疫原性高。
  • IS2和IS3亚型免疫细胞浸润丰富,IS1亚型富含调节性T细胞和自然杀伤细胞。
  • NAMPT、SLC11A1、TNC、VIM和SPP1五个标志物可预测免疫检查点阻断疗效。

核心结论

  • 获得3种可靠的免疫亚型,IS2亚型患者适合免疫治疗,NAMPT、SLC11A1、TNC、VIM和SPP1是低级别胶质瘤组免疫检查点阻断的预测面板标志物。
  • 研究结果为低级别胶质瘤患者的免疫治疗选择和预后预测提供了依据。

研究设计与样本

  • 整合RNA测序数据集和临床信息,进行一致性聚类分析以探索最适合免疫检查点治疗的患者。
  • 采用基因集富集分析、UMAP分析、突变相关性分析、TIMER分析和TIDE分析鉴定3种免疫亚型的免疫特征及5种抗原作为免疫检查点标志物的可行性。

主要发现

  • 3种免疫亚型的同源重组修复基因分离明显,IS2亚型有大量同源重组修复基因突变,增加肿瘤免疫原性,与3种免疫亚型肿瘤突变负荷分析结果一致。
  • IS2和IS3亚型免疫细胞浸润丰富,IS1亚型有较多调节性T细胞和自然杀伤细胞。
  • 3种亚型免疫检查点基因表达分析中,IS2亚型上调最多。
  • 通过TIDE分析和TISIDB分析获得5个可预测低级别胶质瘤患者免疫检查点阻断疗效的标志物。
  • 生存分析证实5个标志物与不良预后相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main treatment of low-grade glioma (LGG) is still surgical resection followed by radiotherapy and/or chemotherapy, which has certain limitations, including side effects and drug resistance. Immunotherapy is a promising treatment for LGG, but it is generally hindered by the tumor microenvironment with the limited expression of tumor antigens. METHODS: We integrated RNA sequencing data sets and clinical information and conducted consistent cluster analysis to explore the most suitable patients for immune checkpoint therapy. Gene set enrichment analysis, UMAP analysis, mutation correlation analysis, TIMER analysis, and TIDE analysis were used to identify the immune characteristics of 3 immune subtypes and the feasibility of 5 antigens as immune checkpoint markers. RESULTS: We analyzed the isolation and mutation of homologous recombination repair genes (HRR) of the 3 immune subtypes, and the HRR genes of the 3 subtypes were obviously segregated. Among them, the IS2 subtype has a large number of HRR gene mutations, which increases the immunogenicity of tumors-this is consistent with the results of tumor mutation load analysis of 3 immune subtypes. Then we evaluated the immune cell infiltration of immune subtypes and found that IS2 and IS3 subtypes were rich in immune cells. It is worth noting that there are many Treg cells and NK cells in the IS1 subtype. In addition, when analyzing the immune checkpoint gene expression of the 3 subtypes, we found that they were upregulated most in IS2 subtypes compared with other subtypes. Then when we further confirmed the role of immune-related genes in LGG; through TIDE analysis and TISIDB analysis, we obtained 5 markers that can predict the efficacy of ICB in patients with LGG. In addition, we confirmed that they were associated with poor prognosis through survival analysis. CONCLUSIONS: We obtained 3 reliable immune subtypes, and patients with the IS2 subtype are suitable for immunotherapy, in which NAMPT, SLC11A1, TNC, VIM, and SPP1 are predictive panel markers for ICB in the LGG group. Our findings provide a rationale for immunotherapy selection and prediction of patient prognosis in LGG patients.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lv Q, Zhang Z, Fu H, et al. Predictive Panel for Immunotherapy in Low-Grade Glioma. World Neurosurg. 2024. PMID: 38216032. doi:10.1016/j.wneu.2024.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。